Successful targeted treatment of mast cell activation syndrome with tofacitinib

Keyphrases

• Activation Syndrome 100%
• Cell Proliferation 25%
• Chronic Inflammatory Diseases 25%
• Clinical Benefit 25%
• Clinical Trials 25%
• Constitutively Activating mutation 25%
• Cytokine Receptor 25%
• Downstream Effectors 25%
• Drug Class 25%
• Heterogeneous Patterns 25%
• Illness 25%
• Inflammatory Effects 25%
• JAK3 Inhibitor 25%
• Janus Kinase 50%
• Janus Kinase 1 (JAK1) 25%
• Mast Cell Activation 25%
• Mast Cell Activation Syndrome 100%
• Mast Cells 50%
• Mastocytosis 25%
• Multisystem 25%
• Mutational Profile 25%
• Polymorbidity 25%
• Regulatory Elements 25%
• Rheumatoid Arthritis 25%
• Symptom Response 25%
• Targeted Treatment 100%
• Tofacitinib 100%

Biochemistry, Genetics and Molecular Biology

• Cell Activation 100%
• Cell Proliferation 20%
• Clinical Trial 20%
• Cytokine Receptor 20%
• Janus Kinase 1 40%
• Mast Cell 100%
• Regulatory Element 20%
• Tofacitinib 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Trial 16%
• Cytokine Receptor 16%
• Disease 33%
• Inflammatory Arthritis 16%
• Janus Kinase 1 33%
• Janus Kinase 3 Inhibitor 16%
• Mastocytosis 16%
• Rheumatoid Arthritis 16%
• Syndrome 100%
• Tofacitinib 100%